ENGN enGene Holdings Inc.

NASDAQ
$1.85

enGene Holdings Inc. (ENGN) is expected to report earnings on December 8, 2026, before the market open. The consensus earnings estimate is a loss of $0.44 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +1.7% since its last earnings release on September 8, 2026.

enGene Reported In-line with Estimates
Tuesday, September 8, 2026 · 7:30 AM ET
Earnings Date
4th Quarter, Oct 2026
Dec 8
Tuesday · 9:00 AM ET
Earnings Whisper
-
vs ($0.44) (GAAP)
Rev est $999
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP -

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About enGene Holdings Inc.

enGene Holdings Inc. is a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues. enGene Holdings Inc., formerly known as Forbion European Acquisition Corp., is based in MONTREAL.

Sector

Healthcare

Industry

Biotechnology